Erratum: Phenylalanine hydroxylase deficiency: Diagnosis and management guideline (Genetics in Medicine (2014) 16:2 (188-200) DOI:10.1038/gim.2013.157);Phenylalanine hydroxylase deficiency: Diagnosis and management guideline

Genetics in Medicine

Volumn 16, Issue 2, 2014, Pages 188-200

  Vockley, Jerry ^a,b   Andersson, Hans C ^c   Antshel, Kevin M ^d   Braverman, Nancy E ^e   Burton, Barbara K ^f   Frazier, Dianne M ^g   Mitchell, John ^e   Smith, Wendy E ^h   Thompson, Barry H ⁱ   Berry, Susan A ^j  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SYRACUSE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h MAINE MEDICAL CENTER   (United States)

ⁱ American College of Medical Genetics   (United States)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

maternal PKU; phenylalanine hydroxylase deficiency; phenylketonuria; sapropterin; therapy

Indexed keywords

AMINO ACID; LARGE NEUTRAL AMINO ACID; PHENYLALANINE; PHENYLALANINE AMMONIA; PHENYLALANINE DERIVATIVE; SAPROPTERIN; UNCLASSIFIED DRUG;

ARTICLE; DIET THERAPY; HUMAN; PHENYLKETONURIA;

BIOPTERIN; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; INFANT; INFANT, NEWBORN; PHENYLALANINE; PHENYLKETONURIAS; UNITED STATES;

EID: 84898422426     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.15     Document Type: Erratum

References (104)

1. Howell RR. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001;108(4):972-982.
2. Lord J, Thomason MJ, Littlejohns P, et al. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 1999;53:179-186.
3. Dhondt JL, Farriaux JP, Sailly JC, Lebrun T. Economic evaluation of cost-benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism. J Inherit Metab Dis 1991;14:633-639.
4. Lee PJ, Amos A, Robertson L, et al. Adults with late diagnosed phenylketonuria and severe challenging behavior: a randomized placebo-controlled trial of phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry 2009;80(6):631-635.
5. Mitchell JJ. Phenylalanine hydroxylase deficiency. In: Pagon RA, Adam MP, Bird TD, et al. (eds). GeneReviews™ [Internet]. University of Washington, Seattle: Seattle, WA, 2000:1993-2013. http://www.ncbi.nlm.nih.gov/books/ NBK1504/.
6. Kayaalp E, Treacy E, Waters PJ, Byck S, Nowacki P, Scriver CR. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. Am J Hum Genet 1997;61:1309-1317.
7. Scriver CL, Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver C, Beaudet AL, Sly WS (eds). The Metabolic And Molecular Bases Of Inherited Disease. 8th ed. McGraw Hill: New York, NY, 2001:1667-1724.
8. Lindegren M, Krishnaswami S, Fonnesbeck C, et al. Adjuvant Treatment for Phenylketonuria (PKU). Comparative Effectiveness Review No. 56. AHRQ Publication: Rockville, MD, 2012:1-343.
9. Vockley J, Chapman KA, Arnold GL. Development of clinical guidelines for inborn errors of metabolism: commentary. Mol Genet Metab 2013;108:203-205.
10. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
11. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 1993;39:66-71.
12. Shapira EBM, Miller J, Africk D. Plasma Amino Acid Analysis. Biochemical Genetics: A Laboratory Manual. Oxford Press: New York, NY; 1989.
13. McHugh D. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13:230-254.
14. Marquardt G, Rinaldo P. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med 2012;14:648-655.
15. Norman R, Haas M, Wilcken B. International perspectives on the costeffectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy 2009;89:252-260.
16. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011;104:S2-S9.
17. Blau N, Burgard P. Disorders of Phenylalanine and Tetrahydrobiopterin. Physicians' Guide to the Treatment and Follow-up of Metabolic Diseases. Springer: Heidelberg; 2005:89-105.
18. Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet 1999;15:267-272.
19. Levy HL, Milanowski A, Chakrapani A, et al.; Sapropterin Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007;370: 504-510.
20. Güttler F, Guldberg P. Mutation analysis anticipates dietary requirements in phenylketonuria. Eur J Pediatr 2000;159(suppl 2):S150-S153.
21. Zschocke J, Hoffmann GF. PAH gene mutation analysis in clinical practice-comments on mutation analysis anticipates dietary requirements in phenylketonuria. Eur J Pediatr 2000;159(suppl 2):S154-S155.
22. Greeves LG, Patterson CC, Carson DJ, et al. Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia. Arch Dis Child 2000;82:216-221.
23. Trefz FK, Scheible D, Götz H, Frauendienst-Egger G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J Inherit Metab Dis 2009;32:22-26.
24. Weglage J, Ullrich K, Pietsch M, Fünders B, Zass R, Koch HG. No fine motor deficits in patients with untreated non-phenylketonuria hyperphenylalaninaemia. Acta Paediatr 1996;85:320-323.
25. Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in mild atypical phenylketonuria. Eur J Pediatr 1994;153:260-263.
26. Gassió R, Artuch R, Vilaseca MA, et al. Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev Med Child Neurol 2005;47:443-448.
27. Diamond A, Prevor M, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monographs Soc Res Child Dev 1977;62(4):1-206.
28. Weglage J, Pietsch M, Feldmann R, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 2001;49:532-536.
29. Singh RH, Rohr F, Frazier D, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med, e-pub ahead of print 2 January 2014.
30. Ney DM, Gleason ST, vanCalcar SC, et al. Nutrition management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 2009;321:32-39.
31. Singh R, Acosta P, Burton B, et al. Tracking Long-term Outcomes: Development of Care Data Elements (CDE) for Phenylketonuria. 4th GMDI Edication Conference: New Orleans, LA, 2012.
32. Gregory CO, Yu C, Singh RH. Blood phenylalanine monitoring for dietary compliance among patients with phenylketonuria: comparison of methods. Genet Med 2007;9:761-765.
33. Modan-Moses D, Vered I, Schwartz G, et al. Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 2007;30:202-208.
34. Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007;30: 700-707.
35. Ziesch B, Weigel J, Thiele A, et al. Tetrahydrobiopterin (BH(4)) in PKU: effect on dietary treatment, metabolic control, and quality of life. J Inherit Metab Dis 2012;35(6):983-992.
36. Leuret O, Barth M, Kuster A, et al. Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria. J Inherit Metab Dis 2012;35:975-981.
37. Utz JR, Lorentz CP, Markowitz D, et al. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 2012;105:193-197.
38. Gordon P, Thomas JA, Suter R, Jurecki E. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients. Mol Genet Metab 2012;105:672-676.
39. Cunningham A, Bausell H, Brown M, et al. Recommendations for the use of sapropterin in phenylketonuria. Mol Genet Metab 2012;106:269-276.
40. Shintaku H, Ohwada M. Long-term follow-up of tetrahydrobiopterin therapy in patients with tetrahydrobiopterin deficiency in Japan. Brain Dev 2012;35(5):406-410.
41. Trefz FK, Burton BK, Longo N, et al.; Sapropterin Study Group. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009;154:700-707.
42. Matalon R, Michals-Matalon K, Bhatia G, et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis 2006;29:732-738.
43. Longo N, Burton B, Harding C, et al. A Phase 2, Open-Label, Dose-Finding and the Long Term Extension Study to Evaluate the Safety, Efficacy and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Patients With Phenylketonuria. American College of Medical Genetics and Genomics 2012 Annual Meeting: Charlotte, NC, 2012.
44. Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 2010;99(suppl 1):S59-S63.
45. Smith I, Beasley MG, Wolff OH, Ades AE. Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register. J Pediatr 1988;112:403-408.
46. Smith I, Knowles J. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr 2000;159(suppl 2):S89-S93.
47. Sullivan JE, Chang P. Review: emotional and behavioral functioning in phenylketonuria. J Pediatr Psychol 1999;24:281-299.
48. Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. J Inherit Metab Dis 1991;14:755-764.
49. Burton BK, Leviton L, Vespa H, et al. A diversified approach for PKU treatment: routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab 2013;108:8-12.
50. Simon E, Schwarz M, Roos J, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes 2008;6:25.
51. Bosch AM, Tybout W, van Spronsen FJ, de Valk HW, Wijburg FA, Grootenhuis MA. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. J Inherit Metab Dis 2007;30:29-34.
52. Demirkol M, Gizewska M, Giovannini M, Walter J. Follow up of phenylketonuria patients. Mol Genet Metab 2011;104:S31-S39.
53. Rohr FJ, Doherty LB, Waisbren SE, et al. New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes. J Pediatr 1987;110:391-398.
54. Brown AS, Fernhoff PM, Waisbren SE, et al. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med 2002;4:84-89.
55. Ng TW, Rae A, Wright H, Gurry D, Wray J. Maternal phenylketonuria in Western Australia: pregnancy outcomes and developmental outcomes in offspring. J Paediatr Child Health 2003;39:358-363.
56. Matalon KM, Acosta PB, Azen C. Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 2003;112(6 Pt 2):1534-1536.
57. Tessier R, Nowak E, Assoun M, et al. Maternal phenylketonuria: low phenylalanine might increase the risk of intra uterine growth retardation. J Inherit Metab Dis 2012; 35:993-999.
58. Lee PJ, Ridout D, Walter JH, Cockburn F. Maternal phenylketonuria: report from the United Kingdom Registry 1978-97. Arch Dis Child 2005;90:143-146.
59. Koch R, Hanley W, Levy H, et al. Maternal phenylketonuria: an international study. Mol Genet Metab 2000;71:233-239.
60. Bradburn NC, Wappner RS, Lemons JA, Meyer BA, Roberts RS. Lactation and phenylketonuria. Am J Perinatol 1985;2:138-141.
61. Fox-Bacon C, McCamman S, Therou L, Moore W, Kipp DE. Maternal PKU and breastfeeding: case report of identical twin mothers. Clin Pediatr (Phila) 1997;36:539-542.
62. Srinivasan BS, Evans EA, Flannick J, et al. A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 2010;21:537-551.
63. Mallolas J, Milà M, Lambruschini N, Cambra FJ, Campistol J, Vilaseca MA. Biochemical phenotype and its relationship with genotype in hyperphenylalaninemia heterozygotes. Mol Genet Metab 1999;67:156-161.
64. Pietz J, Dunckelmann R, Rupp A, et al. Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr 1998;157:824-830.
65. Burgard P. Development of intelligence in early treated phenylketonuria. Eur J Pediatr 2000;159(suppl 2):S74-S79.
66. Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002;25:333-346.
67. Waisbren SE, Schnell RR, Levy HL. Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome. J Inherit Metab Dis 1980;3:149-153.
68. Azen C, Koch R, Friedman E, Wenz E, Fishler K. Summary of findings from the United States Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S29-S32.
69. Fishler K, Azen CG, Henderson R, Friedman EG, Koch R. Psychoeducational findings among children treated for phenylketonuria. Am J Ment Defic 1987;92:65-73.
70. Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 2007;17:91-101.
71. Sternberg RJ, Grigorenko EL. Intelligence and culture: how culture shapes what intelligence means, and the implications for a science of well-being. Philos Trans R Soc Lond, B, Biol Sci 2004;359:1427-1434.
72. Pennington BF, van Doorninck WJ, McCabe LL, McCabe ER. Neuropsychological deficits in early treated phenylketonuric children. Am J Ment Defic 1985;89:467-474.
73. Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 1990;61:1697-1713.
74. Weglage J, Ullrich K, Pietsch M, Fünders B, Zass R, Koch HG. Untreated nonphenylketonuric-hyperphenylalaninaemia: intellectual and neurological outcome. Eur J Pediatr 1996;155 Suppl 1:S26-S28.
75. Huijbregts SC, de Sonneville LM, van Spronsen FJ, Licht R, Sergeant JA. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci Biobehav Rev 2002;26:697-712.
76. Stemerdink BA, van der Meere JJ, van der Molen MW, et al. Information processing in patients with early and continuously-treated phenylketonuria. Eur J Pediatr 1995;154:739-746.
77. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 1994;124:388-392.
78. Christ SE, Huijbregts SC, de Sonneville LM, White DA. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 2010;99(suppl 1):S22-S32.
79. Sharman R, Sullivan K, Young R, McGill J. Biochemical markers associated with executive function in adolescents with early and continuously treated phenylketonuria. Clin Genet 2009;75:169-174.
80. Brumm VL, Grant ML. The role of intelligence in phenylketonuria: a review of research and management. Mol Genet Metab 2010;99 (suppl 1):S18-S21.
81. Gassió R, Fusté E, López-Sala A, Artuch R, Vilaseca MA, Campistol J. School performance in early and continuously treated phenylketonuria. Pediatr Neurol 2005;33:267-271.
82. Antshel KM, Waisbren SE. Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology 2003;17:458-468.
83. Channon S, German E, Cassina C, Lee P. Executive functioning, memory, and learning in phenylketonuria. Neuropsychology 2004;18:613-620.
84. Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 1990;65:472-478.
85. DeRoche K, Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function. Dev Neuropsychol 2008;33:474-504.
86. Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007;92:63-70.
87. Antshel KM, Waisbren SE. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol 2003;31:565-574.
88. Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis 2004;27:137-143.
89. Gentile JK, Ten Hoedt AE, Bosch AM. Psychosocial aspects of PKU: hidden disabilities-a review. Mol Genet Metab 2010;99(suppl 1):S64-S67.
90. Kazak AE, Reber M, Snitzer L. Childhood chronic disease and family functioning: a study of phenylketonuria. Pediatrics 1988;81:224-230.
91. Waisbren S, White DA. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol Genet Metab 2010;99(suppl 1):S96-S99.
92. DeNavas-Walt C, Proctor BD, Smith JC. U.S. Census Bureau, Current Population Reports, P60-239. Income, Poverty, and Health Insurance Coverage in the United States: 2010. U.S. Government Printing Office: Washington, DC, 2011.
93. American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians, Transitions Clinical Report Authoring Group, Cooley WC, Sagerman PJ. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 2011;128:182-200.
94. Crowley R, Wolfe I, Lock K, McKee M. Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child 2011;96:548-553.
95. Harden PN, Walsh G, Bandler N, et al. Bridging the gap: an integrated paediatric to adult clinical service for young adults with kidney failure. BMJ 2012;344:e3718.
96. Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 2007;28:831-845.
97. Bayley N. Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III). Pearson Publishing: San Antonio, TX; 2005.
98. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence - Third Edition (WPPSI-III). Pearson Publishing: San Antonio, TX; 2002.
99. Wechsler D. Wechsler Abbreviated Scale of Intelligence - 2nd edition (WASI-II). Pearson Publishing: San Antonio, TX; 2011.
100. Gioia GA, Peter K, Guy S, Kenworthy L. Behavior Rating Inventory of Executive Functioning (BRIEF). PAR: Lutz, FL; 2000.
101. Kamphaus RW. The Behavioral Assessment System for Children - Second edition. American Guidance Service: Circle Pines, MN; 2005.
102. Beck AT, Steer RA, Brown G. Beck Depression Inventory - 2nd edition (BDI-II). Pearson Publishing: San Antonio, TX; 1996.
103. Beck A. Beck Anxiety Inventory (BAI). Pearson Publishing: San Antonio, TX; 1993.
104. Harrison P, Oakland T. Adaptive Behavior Assessment System-Second Edition (ABAS-II). Pearson Publishing: San Antonio, TX; 2003.